The bill replaces vague judicial exceptions with statutory, claim-focused rules that aim to clarify and narrow patent eligibility—protecting many machine- and biotech-linked inventions and curbing overly broad patents—while creating mixed, sometimes conflicting effects that raise litigation risk, biotech uncertainty, and uneven impacts on software and method-related innovators.
Inventors, researchers, and companies gain clearer, statutory standards for patent eligibility, reducing legal uncertainty when filing and litigating patents.
Tech workers, device makers, and startups that tie inventions to machines (including computers) retain stronger eligibility for patents on machine- or device-based inventions, protecting hardware- and device-integrated software innovations.
Biotech companies and biomedical researchers can patent modified, purified, or engineered genes and natural materials used in inventions, preserving protections for many diagnostics, therapeutics, and engineered biological products.
Small businesses, startups, and consumers may face higher licensing costs because some changes could expand patentability for software-implemented inventions, enabling more enforceable patents and licensing claims.
Software developers and startups may lose protection for inventions that only use generic computers because narrower rules for computer-implemented claims could bar some software patents, reducing investment incentives.
Biotech firms, researchers, and patients face uncertainty because ambiguity about what counts as a 'modified' natural gene or material could spur litigation and delay development or commercialization of diagnostics and therapies.
Based on analysis of 4 sections of legislative text.
Introduced May 1, 2025 by Thomas Roland Tillis · Last progress May 1, 2025
Changes patent-eligibility law by removing the judicially created exceptions and replacing them with a statutory rule that broadly makes any useful process, machine, manufacture, composition of matter, or useful improvement eligible for patent protection, subject to a short list of explicit exclusions. It adds definitions (including a broadened definition of “process” and a statutory meaning of “useful”), directs courts to assess eligibility based on the whole claimed invention without importing novelty/obviousness/enablement considerations, and allows courts to decide eligibility early in litigation with limited discovery. The law explicitly excludes certain categories from eligibility: pure mathematical formulas standing alone, mental processes performed solely in the human mind, unmodified human genes and unmodified natural materials as they exist in nature, and processes that are substantially economic/financial/business/social/cultural/artistic (with rules to prevent simple computer recitations from making a purely human-conduct process eligible). It also preserves existing patentability doctrines like novelty, nonobviousness, and written-description as separate gates to patenting.